Proprietary technologies in LNP-based delivery of mRNA and DNA vectors to advance T-CURX innovative in vivo CAR-T assets into clinical trials one year earlier
MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease
The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis
First-in-human study of investigational SOS1 inhibitor shows encouraging safety profile and early anti-tumor activity in patients with metastatic solid tumors
BPDCN typically presents with skin lesions before rapidly spreading to the bone marrow, lymph nodes
The newly licensed platform enables precise control over both the drug-to-antibody ratio and payload attachment sites in single- and dual-payload ADCs
On a full-year basis, revenue from operations for FY26 grew 18.9 percent year-on-year to Rs 827.87 crore compared to Rs 696.48 crore in FY25
In his new role, Shisher will lead Glenmark’s marketing initiatives, focusing on strengthening brand positioning, driving market expansion, and accelerating growth
These data support clinically meaningful efficacy within this patient population. We observed a high rate of complete responses in patients with laCSCC
Subscribe To Our Newsletter & Stay Updated
